Matthew Strobeck Buys 40,000 Shares of Biodesix, Inc. (NASDAQ:BDSX) Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Matthew Strobeck acquired 40,000 shares of Biodesix stock in a transaction dated Tuesday, November 5th. The shares were purchased at an average price of $1.40 per share, with a total value of $56,000.00. Following the acquisition, the director now owns 2,606,879 shares of the company’s stock, valued at approximately $3,649,630.60. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Biodesix Stock Performance

Shares of NASDAQ:BDSX opened at $1.33 on Friday. The business’s 50 day simple moving average is $1.69 and its 200 day simple moving average is $1.61. Biodesix, Inc. has a 1 year low of $1.15 and a 1 year high of $2.21. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.40 and a quick ratio of 3.28.

Biodesix (NASDAQ:BDSX) last released its earnings results on Friday, November 1st. The company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. The company had revenue of $18.15 million for the quarter, compared to analyst estimates of $18.45 million. During the same period in the prior year, the firm posted ($0.12) EPS. On average, sell-side analysts anticipate that Biodesix, Inc. will post -0.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BDSX has been the subject of several recent research reports. Craig Hallum assumed coverage on Biodesix in a research note on Friday, July 26th. They issued a “buy” rating and a $3.00 price target for the company. Scotiabank began coverage on Biodesix in a report on Monday, September 16th. They set a “sector outperform” rating and a $3.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $3.06.

Hedge Funds Weigh In On Biodesix

Several hedge funds have recently bought and sold shares of BDSX. Perkins Capital Management Inc. lifted its holdings in shares of Biodesix by 74.7% during the 3rd quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock worth $1,290,000 after acquiring an additional 310,000 shares during the period. Perceptive Advisors LLC acquired a new position in Biodesix during the second quarter valued at approximately $3,326,000. CVI Holdings LLC acquired a new stake in shares of Biodesix in the 2nd quarter valued at $59,000. Farallon Capital Management LLC acquired a new position in shares of Biodesix during the 2nd quarter worth $2,874,000. Finally, AIGH Capital Management LLC boosted its stake in Biodesix by 74.0% in the second quarter. AIGH Capital Management LLC now owns 5,779,812 shares of the company’s stock valued at $8,843,000 after buying an additional 2,458,727 shares in the last quarter. 20.96% of the stock is owned by institutional investors.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.